
Claims:

1. A compound of formula (I) for use in a method of treating a subject suffering from or diagnosed with depression, comprising administering to a subject in need of such treatment an effective amount of a compound of formula (I):



(I)

wherein:

R_1 is C_{1-4} alkyl;

R_2 is C_{1-4} alkyl;

R_3 is H or halogen; and

R_4 is H or C_{1-4} alkoxy;

or a pharmaceutically acceptable salt or hydrate thereof,

wherein the compound is administered prior to sleep.

2. The compound of formula (I) for use according to claim 1 wherein the subject is not suffering from or diagnosed with an insomnia disorder.

3. The compound of formula (I) for use according to claim 1, wherein R^3 is halogen, optionally fluorine.

4. The compound of formula (I) for use according to claim 1, wherein R^4 is H.

5. The compound of formula (I) for use according to claim 1, wherein R^4 is $C_{1\text{-}4}$alkoxy, optionally methoxy.

6. The compound of formula (I) for use according to claim 1, wherein R^3 is H.

7. The compound of formula (I) for use according to claim 1, wherein R^1 is CH_3.

8. The compound of formula (I) for use according to claim 1, wherein R^2 is CH_3.

9. The compound of formula (I) for use according to claim 1, wherein the compound is 5-(4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone or a pharmaceutically acceptable salt thereof.

10. The compound of formula (I) for use according to claim 1, wherein the compound is 5-(4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone.

11. The compound of formula (I) for use according to claim 1, wherein the compound is 5-(4,6-dimethyl-pyrimidin-2-yl)-hexahydro-pyrrolo[3,4-c]pyrrol-2-yl]-(2-fluoro-6-[1,2,3]triazol-2-yl-phenyl)-methanone hydrochloride.

12. The compound of formula (I) for use according to claim 1, wherein the compound is (5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone or a pharmaceutically acceptable salt thereof.

13. The compound of formula (I) for use according to claim 1, wherein the compound is (5-(4,6-dimethylpyrimidin-2-yl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)(4-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone.

14. The compound of formula (I) for use according to claim 1, wherein the compound is administered at night.

15. The compound of formula (I) for use according to claim 1, wherein the compound is administered at daily.

16. The compound of formula (I) for use according to claim 1, wherein the compound is administered orally.

17. The compound of formula (I) for use according to claim 1, wherein the effective amount is about 10 to about 40 mg.

18. The compound of formula (I) for use according to claim 1, wherein the depression comprises major depressive disorder, depression associated with bipolar disease, or treatment resistant depression, optionally wherein the depression is major depressive disorder or treatment resistant depression.

19. The compound of formula (I) for use according to claim 1, further comprising administering a second antidepressant, optionally wherein said second antidepressant is a selective serotonin reuptake inhibitor, serotonin and noradrenaline reuptake inhibitor, or combinations thereof.

20. The compound for use according to claim 9, wherein the subject is not suffering from or diagnosed with an insomnia disorder.

21. The compound for use according to claim 9 or 20, wherein the compound is administered at night.

22. The compound for use according to any one of claims 9, 20 or 21, wherein the depression is major depressive disorder.

23. The compound for use according any one of claims 9 or 20-22, further comprising administering a second antidepressant.

24. The compound for use according to claim 23, wherein the second antidepressant is a selective serotonin reuptake inhibitor, serotonin and noradrenaline reuptake inhibitor, or combinations thereof.

25. The compound for use according to claim 23 or 24, wherein the effective amount of the compound is about 10 to about 40 mg.

26. The compound for use according to claim 23 or 24, wherein the effective amount of the compound is about 20 mg.

27. The compound for use according to claim 25 or 26, wherein the compound is administered once daily.